FDA panel zaps Zogenix Zohydro: Rough road ahead for other ER opioids?
This article was originally published in Scrip
Executive Summary
The chances Zogenix would convince a US FDA panel to back approval of the firm's extended-release (ER) single-entity hydrocodone analgesic Zohydro ER were slim going into the 7 December meeting, given regulators already stated outright there is a high likelihood for abuse and misuse of the medicine.